Literature DB >> 9885900

Preferred CDRH3 lengths for antibodies with defined specificities.

G Johnson1, T T Wu.   

Abstract

The third complementarity determining regions of heavy chain variable regions (CDRH3) confer the fine specificities of antibodies. The CDRH3 length distribution of all human or all mouse antibodies appears to be more or less random, with the human distribution having a wider spread. Since the Kabat database of aligned amino and nucleotide sequences of proteins of immunological interest has grown at least 4 times during the past 7 years, we attempt to study CDRH3 length distributions of human and mouse antibodies with defined specificities, where enough complete and distinct CDRH3 sequences are available. For mouse antibodies against small haptens or carbohydrates, a preferred length usually dominates for a given specificity. There are not enough human sequences of small hapten or carbohydrate antibodies for a similar study. Both human and mouse anti-protein antibodies have wider ranges of CDRH3 length distributions, probably due to the presence of different antigenic epitopes on the protein molecules, and thus many different antibodies. For anti-DNA antibodies, both humans and mice exhibit even wider length distributions, since DNA can be double stranded, single stranded, supercoiled, etc.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9885900     DOI: 10.1093/intimm/10.12.1801

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  23 in total

1.  Kabat database and its applications: 30 years after the first variability plot.

Authors:  G Johnson; T T Wu
Journal:  Nucleic Acids Res       Date:  2000-01-01       Impact factor: 16.971

2.  Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization.

Authors:  Mikyung Kim; Zhen-Yu J Sun; Kasper D Rand; Xiaomeng Shi; Likai Song; Yuxing Cheng; Amr F Fahmy; Shreoshi Majumdar; Gilad Ofek; Yongping Yang; Peter D Kwong; Jia-Huai Wang; John R Engen; Gerhard Wagner; Ellis L Reinherz
Journal:  Nat Struct Mol Biol       Date:  2011-10-16       Impact factor: 15.369

3.  Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding.

Authors:  Jean-Philippe Julien; Nerea Huarte; Rubén Maeso; Stefka G Taneva; Annie Cunningham; José L Nieva; Emil F Pai
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

4.  6th Annual European Antibody Congress 2010: November 29-December 1, 2010, Geneva, Switzerland.

Authors:  Alain Beck; Thierry Wurch; Janice M Reichert
Journal:  MAbs       Date:  2011-03-01       Impact factor: 5.857

5.  Genetic removal of the CH1 exon leads to the production of hypofunctional heavy chain-only IgG2a in rats.

Authors:  Zhenrong Li; Ming Zhang; Shunan Zheng; Yu Song; Xueqian Cheng; Di Yu; Lijuan Du; Liming Ren; Haitang Han; Yaofeng Zhao
Journal:  Transgenic Res       Date:  2020-02-20       Impact factor: 2.788

6.  Rapid isolation of a single-chain antibody against the cyanobacterial toxin microcystin-LR by phage display and its use in the immunoaffinity concentration of microcystins from water.

Authors:  Jacqui McElhiney; Mathew Drever; Linda A Lawton; Andy J Porter
Journal:  Appl Environ Microbiol       Date:  2002-11       Impact factor: 4.792

7.  Structure-based design of a protein immunogen that displays an HIV-1 gp41 neutralizing epitope.

Authors:  Robyn L Stanfield; Jean-Philippe Julien; Robert Pejchal; Johannes S Gach; Michael B Zwick; Ian A Wilson
Journal:  J Mol Biol       Date:  2011-10-15       Impact factor: 5.469

8.  Defining the complementarities between antibodies and haptens to refine our understanding and aid the prediction of a successful binding interaction.

Authors:  Mohammed M Al Qaraghuli; Soumya Palliyil; Gillian Broadbent; David C Cullen; Keith A Charlton; Andrew J Porter
Journal:  BMC Biotechnol       Date:  2015-10-24       Impact factor: 2.563

9.  Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop.

Authors:  Joshua M Costin; Elena Zaitseva; Kristen M Kahle; Cindo O Nicholson; Dawne K Rowe; Amanda S Graham; Lindsey E Bazzone; Greg Hogancamp; Marielys Figueroa Sierra; Rachel H Fong; Sung-Tae Yang; Li Lin; James E Robinson; Benjamin J Doranz; Leonid V Chernomordik; Scott F Michael; John S Schieffelin; Sharon Isern
Journal:  J Virol       Date:  2012-10-17       Impact factor: 5.103

10.  Production, purification, crystallization and preliminary X-ray diffraction analysis of the HIV-2-neutralizing V3 loop-specific Fab fragment 7C8.

Authors:  Hannes Uchtenhagen; Samer Sourial; Rosmarie Friemann; Mariethe Ehnlund; Anna-Lena Spetz; Robert A Harris; Chaithanya Madhurantakam; Adnane Achour
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.